Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells

Nat Rev Clin Oncol. 2014 Dec;11(12):685-6. doi: 10.1038/nrclinonc.2014.190. Epub 2014 Nov 11.


Adoptive immunotherapy using T cells genetically engineered to express a chimeric antigen receptor that targets CD19, a B-cell differentiation antigen, has demonstrated impressive efficacy in a range of B-lymphoid malignancies. The latest results demonstrate the potential of this approach in patients with chemotherapy-refractory diffuse large B-cell lymphoma.

Publication types

  • News

MeSH terms

  • Antigens, CD19 / metabolism*
  • Humans
  • Immunotherapy / methods*
  • Lymphoma / drug therapy*
  • Treatment Outcome


  • Antigens, CD19